Metabolism - Clinical and Experimental
Volume 46, Issue 8 , Pages 908-913, August 1997

Estrogen therapy enhances calcium absorption and retention and diminishes bone turnover in young girls with turner's syndrome: A calcium kinetic study

  • Nelly Mauras

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Nelly Mauras, MD, Nemours Children's Clinic, 807 Nira St, Jacksonville, FL 32207.
    • Nemours Children's Clinic, Jacksonville, FL USA
    • Laboratory of Theoretical and Physical Biology, National Institute of Child Health and Human Development (NICHD), National Institutes of Health, Bethesda, MD USA
  • ,
  • Nancy E. Vieira

      Affiliations

    • Nemours Children's Clinic, Jacksonville, FL USA
    • Laboratory of Theoretical and Physical Biology, National Institute of Child Health and Human Development (NICHD), National Institutes of Health, Bethesda, MD USA
  • ,
  • Alfred L. Yergey

      Affiliations

    • Nemours Children's Clinic, Jacksonville, FL USA
    • Laboratory of Theoretical and Physical Biology, National Institute of Child Health and Human Development (NICHD), National Institutes of Health, Bethesda, MD USA

Received 18 September 1996; accepted 21 February 1997.

Abstract 

Using stable tracers of calcium, we have previously shown a significant increase in calcium absorption and retention in prepubertal boys treated with exogenous testosterone. To investigate the effects of estrogen replacement on measures of calcium absorption, retention, and bone turnover, we studied a group of seven hypogonadal girls with Turner's syndrome (mean± SE age, 12.5 ± 0.7 years). At baseline, 42Ca intravenously (IV) and 44Ca orally were administered, and blood and urine samples were collected for approximately 130 hours. Estrogen therapy was begun as oral ethinyl estradiol (4 or 20 μg/d) or intramuscular depot estradiol given over 4 weeks, after which an identical study was repeated. Analysis of calcium enrichment in blood and urine was performed using mass spectrometry methods. After estrogen therapy, there was a significant increase in calcium absorption ([Va] P = .03) and total calcium retention ([Vbal] P = .04), similar to the effects of testosterone in boys. Bone accretion (Vo+) decreased after estrogen therapy (P = .004), as did resorption ([Vo] P = .004). The overall rate of whole-body calcium turnover (Vt) was significantly decreased after estrogen administration (P = .04). These findings were opposite of those observed in prepubertal boys treated with testosterone. The contribution of bone resorption to whole-body turnover (E) also decreased after estrogen therapy (P = .05). These changes were associated with increased levels of 1,25-dihydroxyvitamin D after therapy with estrogens (P = .05). We conclude that estrogen supplementation is significantly anabolic for calcium metabolism by markedly increasing calcium absorption and retention and diminishing the estimated whole-body calcium turnover in girls with severe hypogonadism and Turner's syndrome. Further studies assessing the dietary calcium and/or vitamin D intake and bone mineral density of hypogonadal girls whose estrogen replacement is intentionally delayed will further define the need for calcium or vitamin D supplements in the peripubertal years in this condition.

No full text is available. To read the body of this article, please view the PDF online.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by Nemours Research Programs, Jacksonville, FL, and the NICHD, National Institutes of Health, Bethesda, MD.

PII: S0026-0495(97)90078-0

Metabolism - Clinical and Experimental
Volume 46, Issue 8 , Pages 908-913, August 1997